Neuroimmunology, Neurological disorders and Neurogenetics

Biography:

CEO & Founder - Biotechnology and Regenerative Medicine at RegenerAge International ™ (www.regenerage.clinic) VP of International Clinical Development for Bioquark, Inc. (www.bioquark.com) Chief Clinical Officer at ReAnima™ Advanced Biosciences (www.reanima.tech) Westhill University School of Medicine. Mexico Advance Fellow by the American Board of AntiAging and Regenerative Medicine (A4M) Visiting scholar at University of North Carolina at Chapel Hill (Dermatology) Fellow in Stem Cell Medicine by the American Academy of Anti-Aging Medicine and University of South Florida

 

Abstract:

As it has been previously demonstrated that coelectroporation of Xenopus laevis frog oocytes with normal cells and cancerous cell lines induces the expression of pluripotency markers, and in experimental murine model studies that mRNA extract (Bioquantine® purified from intra- and extra-oocyte liquid phases of electroporated oocytes) showed potential as a treatment for a wide range of conditions as Squint, Spinal Cord Injury (SCI) and Cerebral Palsy among others. The current study observed beneficial changes with Bioquantine® administration in a patient with a severe SCI. Pluripotent stem cells have therapeutic and regenerative potential in clinical situations CNS disorders even cancer.2-3- 7 One method of reprogramming somatic cells into pluripotent stem cells is to expose them to extracts prepared from Xenopus laevis oocytes1 We showed previously that coelectroporation of Xenopus laevis frog oocytes; with normal cells and cancerous cells lines, induces expression of markers of pluripotency.4 We also observed therapeutic effects of treatment with a purified extract (Bioquantine) of intra- and extra-oocyte liquid phases derived from electroporated X. laevis oocytes, on experimentally induced pathologies including murine models of melanoma, traumatic brain injury, and experimental skin wrinkling induced by squalenemonohydroperoxide (Paylian et al, 2016).

The positive human findings for Spinal Cord Injury, and Cerebral Palsy with the results from previous animal studies with experimental models of traumatic brain injury, respectively (Paylian et al, 2016). Because of ethical reasons, legal restrictions, and a limited numbers of patients, we were able to treat only a very small number of patients. These results indicate that Bioquantine ® may be safe and well tolerated for use in humans, and deserves further study in a range of degenerative disorders. We propose that the mechanism of action of Bioquantine® in these various diseases derives from its unique pharmacology and combinatorial reprogramming properties. In conclusion, these preliminary findings suggest that Bioquantine is safe and well tolerated on patients with Cerebral Palsy and- Spinal Cord Injury, among others. In addition to the regenerative therapy and due to the patient condition, we decided to include the Restore- Sensor SureScan5-6 . Based on the of electrical stimulation for rehabilitation and regeneration after spinal cord injury published by Hamid and MacEwan 8-9 , we designed an improved delivery method for the in situ application of MSCs and Bioquantine® in combination with the RestoreSensor® SureScan® Conclusions: To the present day the patient who suffered a total section of spinal cord at T12-L1 shows an improvement in sensitivity, strength in striated muscle and smooth muscle connection, 11 months after the first therapy of cell regeneration and 3 month after the placement of RestoreSensor ® at the level of the lesion, the patient with a complete medullary section shows an evident improvement on his therapy of physical rehabilitation on crawling from front to back by himself and standing on his feet for the first time and showing a progressively important functionality on the gluteal and legs sensitivity

 

Biography:

Dr. Denis Gris has started his scientific career with the Master's and Ph.D. in Neuroscience at Dr. Lynn Weaver's laboratory at the University of Western Ontario. He studied the role of inflammation in spinal cord injury. He discovered that the influx of neutrophils is detrimental for recovering after spinal cord injury. Using anti CD11d antibody as a treatment, he demonstrated that animals recovered faster and better after the treatment. Also, he showed that sever spinal cord injury results in massive inflammatory reactions throughout the body leading to syndrome similar to multiple organ dysfunction syndrome. Dr. Denis Gris continued his education in Dr. Jenny P-Y Ting's laboratory as a post-doctoral fellow at the University of North Carolina at Chapel Hill. There he studied in detail mechanism of activation of innate and adoptive immune responses. In collaboration with Dr. Wen, Dr. Eitas, Dr. Allen, and other members of the laboratory, Dr. Gris studied inflammation during obesity which leads to insulin resistance; innate and adoptive responses during multiple sclerosis. In summary, his role in this laboratory was to define the role of novel family of immuno regulatory proteins (NLRs) in different human diseases. Currently, Dr. Denis Gris is a member of Immunology Program at the University of Sherbrooke and he is studying neuro-immune interactions during healthy state and disease.

 

Abstract:

Recently developed various automated video assessment systems that measure mouse behavior produce enormous data sets. The analysis of such multidimensional behavioral data is a difficult task. The questions such as what parameters to use and how to combine similar behavioral parameters into various categories require an application of unbiased statistical approaches. We have developed simple and at the same time powerful protocol of behavioral analysis using R programming. Using this protocol in a mouse model of multiple sclerosis we have characterized a behavioral signature of neuroinflammation. Multiple sclerosis is an autoimmune disease of the central nervous system. Recently, we have discovered an endogenous pathway that limits inflammation in a multiple sclerosis-like disease in mice.    One of the key molecules of these pathways is Nlrx1 that belongs to Nlr family of proteins.  Nlrs bind multiple proteins inside cells thus redirecting molecular signalling. Using state-of-the-art automated behavioral platform, we demonstrate that Nlrx1 inhibits progression of the diseases in a mouse model of MS. Furthermore we were able to construct mice with an increased predisposition to MS. These mice demonstrate the spontaneous appearance of the disease without any immunization. This model helped us to dissociate the sickness behavioral profile from the behavioral signature of neuroinflammation. We have grouped 33 behavioral activities into clusters and factors that enabled us to reveal signs of neuroinflammation within the first week after the disease induction.

In addition, we noted significant differences in the circadian rhythm of mice with the neuroinflammatory component.

In conclusion, the approach that we used in our study to analyze behavioral signature of neuroinflammation presents highly sensitive, automated, and easy-to-use tool that can be applied to evaluate progression of neurodegenerative diseases and various treatment paradigms.